Actively Recruiting
Phase 3 Study of Armatinib Alone or With Stereotactic Radiotherapy for EGFR-mutated Non-small Cell Lung Cancer Brain Metastases
Led by Shanghai Cancer Hospital, China · Updated on 2023-04-05
300
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying patients with asymptomatic or minimally symptomatic Stage IV non-small cell lung cancer NSCLC that has spread to the brain, specifically those with mutations in the EGFR gene. The study aims to evaluate the timing, effectiveness, and safety of radiotherapy combined with or without the drug Almonertinib for brain metastases in these patients. This is a Phase III, randomized, double-blind clinical trial sponsored by Shanghai Cancer Hospital, China. Participants receive treatment with Almonertinib at a dose of 110 mg per day taken orally. Some patients also receive stereotactic body radiotherapy SBRT directed at brain lesions, with doses ranging from 27 to 40 Gy over 3 to 5 sessions. One study group receives SBRT concurrently with the start of Almonertinib, another group receives SBRT after imaging shows maximal remission from Almonertinib alone, and a third group receives Almonertinib only. During the study, participants are closely monitored with MRI scans to assess brain lesions and evaluate treatment response. The main outcome measured is intracranial progression-free survival over a 12-month period. Researchers also assess safety and tolerability. The study includes regular check-ups involving physical exams, laboratory tests, and imaging. Participants remain in the trial for a duration sufficient to capture these outcomes and may continue follow-up after treatment completion.
CONDITIONS
Brief Title
Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here